Eyepoint Inc

This management proposal asks shareholders to approve Amendment No. 3 to the Company's 2023 Long-Term Incentive Plan to increase the number of shares available for issuance under the plan by 4,900,000 shares. Management argues the increase is required to maintain a competitive equity program to attract, retain and motivate employees, executives and directors in the intensely competitive Cambridge/Boston life sciences labor market and to support the Company’s strategic and operational plans, including product development and potential commercialization. The filing details the current share usage, outstanding awards and available reserve as of April 21, 2026 and models projected future share usage, stating the requested increase is expected to sustain equity grants for approximately 1–2 years. The plan includes governance provisions such as no repricing without shareholder approval, conservative share reuse rules, dividend restrictions, limits on annual non-employee director compensation, and administrator discretion subject to board oversight. Management warns that rejection could impair hiring and retention, force higher cash compensation, and negatively impact the Company's ability to execute its growth strategy. The Board recommends a vote FOR, emphasizing alignment of employee and shareholder interests, pay-for-performance, and the importance of equity incentives to long-term value creation. The proposal also references Annex A (Amendment No. 3) which specifies the revised share limit (increasing the maximum to 15,300,000 shares) and other technical plan language changes that would become effective upon shareholder approval. In evaluating the proposal, investors should weigh the potential dilution (management models an increase in overhang from ~19% to ~25% if fully used) against the retention and incentive benefits, consider the Company's stage, recent equity burn and grant practices, and note that no awards have been granted under the increased reserve prior to shareholder approval.

This non-binding shareholder proposal asks stockholders to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement (the standard “say-on-pay” item). Management frames its executive pay program as market‑competitive and aligned with shareholder interests through a mix of base salary, annual performance-based cash bonuses, and long-term equity (options, RSUs, and performance-based awards). The Compensation Committee engaged an independent consultant (Aon) and set rigorous corporate goals for 2025, resulting in a 150% corporate performance score that materially affected bonus outcomes and resulted in sizable realized compensation for senior executives in 2025; the committee also designed performance options tied to development and regulatory milestones for DURAVYU. The Board recommends a FOR vote, stating it values shareholder feedback and will consider any significant vote against pay when assessing future program design and engagement. Key considerations for investors include the transparency of disclosure, the balance of short- vs long-term incentives, the presence of performance-based milestones (including newly granted performance options tied to regulatory milestones and accelerated vesting), change-in-control and severance protections described for NEOs, and the company’s recent operating performance and equity dilution. Because the vote is advisory, a negative outcome would not directly change pay arrangements but would be expected to trigger further board engagement with major holders and potential program adjustments. For a sophisticated assessment, investors should weigh the alignment created by long-term, milestone-focused equity awards against potential concerns about executive pay levels, the strength of pay-for-performance linkages, and governance safeguards such as clawback and consultant review.